Business Wire

Kurion and Pacific Northwest National Laboratory Sign Agreement to Demonstrate Kurion’s Modular Vitrification System®

Share
CA-KURION-INC

Kurion moving to commercialize its next set of technologies

Kurion, Inc., an innovator in nuclear waste management, announced that it has entered into a cooperation agreement with Pacific Northwest National Laboratory (PNNL ) to test and demonstrate its Modular Vitrification System (MVS® ) using radioactive waste simulants as the next step in its commercialization strategy. All testing and analysis will be performed by PNNL at its Radiochemical Processing Laboratory (RPL , a.k.a. Building 325) located at the U.S. Department of Energy’s Hanford site . Kurion will pay a fee to cover the costs of the testing and will provide an MVS®, replicating an existing non-radioactive system except for slight modifications for research space compatibility. The contract includes specific provisions to preserve PNNL’s unbiased, independent assessment.

“Potential suppliers to the Department of Energy traditionally relied on government funding to test their technologies,” said John Raymont, founder and CEO of Kurion. “With increasing pressure on government budgets, particularly in funding innovative nuclear waste-management technologies, we are breaking from the traditional approach and taking on this development risk ourselves, a trademark of venture capital-backed companies and a value that Kurion brings to its customers.”

Mr. Raymont added, “After demonstrating success with our first technology phase, Ion Specific Media , to clean tens of millions of gallons of contaminated water at the tsunami-damaged Fukushima Daiichi Nuclear Power Plant , the company is now accelerating commercialization of its second phase, the Modular Vitrification System. To do so, it is important to obtain independent and respected neutral validation based on radioactive waste test data, with none more qualified than the scientists at Pacific Northwest National Laboratory, given their experience in testing melter designs and nuclear process science.”

The immediate goal of the PNNL team is to demonstrate the immobilization of radionuclides captured on Kurion Ion Specific Media used by the Tokyo Electric Power Company (TEPCO ) to process highly contaminated water at the Fukushima Daiichi Nuclear Power Plant. The lab will also perform additional demonstrations on the Low Activity Waste (LAW ) feed to the Hanford Waste Treatment and Immobilization Plant (WTP ).

Radioactive simulants will be used to validate Kurion’s internal tests on non-radioactive simulants that show the spent Ion Specific Media processed at Fukushima Daiichi and the LAW feed can successfully be volume reduced and converted into stable borosilicate or iron phosphate glasses through vitrification . Test results will be included in studies to determine whether the Kurion vitrification technology can be effectively implemented to lower the lifecycle cost of permanently stabilizing the Fukushima Daiichi wastes and assist in accelerating and lowering the $59.9 billion lifecycle cost of permanently stabilizing the approximately 56 million gallons of radioactive and chemically hazardous waste stored at the Hanford Tank Farm .

“Kurion has successfully matured its Modular Vitrification System as far as it can go without using confirmatory radioactive simulants,” said Dr. Richard Keenan, vice president of engineering for Kurion. “Working with the world-class scientists and facilities at Pacific Northwest National Laboratory allows Kurion to replicate the non-radioactive testing successfully performed at our MVS® Test Facility using radioactive simulants, develop the highest pedigree of experimental validation, and raise the system’s Technology Readiness Level per the guidelines developed by the Department of Energy as the company moves towards commercialization.”

“More than 70 tests runs over a wide range of waste simulants using the Modular Vitrification System at the Kurion facilities confirm that the technology holds great promise and warrants a thorough independent demonstration,” said Dr. Mark Denton, Kurion’s chief technology officer. “We are pleased that Pacific Northwest National Laboratory has agreed to test and demonstrate our system, which we believe can dramatically reduce lifecycle costs and accelerate compliance for waste management programs at Department of Energy sites , the Fukushima Daiichi Nuclear Power Plant, and nuclear plants and facilities worldwide.”

ABOUT KURION

KURION PROVIDES INNOVATIVE, EASILY DEPLOYABLE TECHNOLOGIES TO ACCELERATE PROJECT PERFORMANCE AND COMPLIANCE AND SUBSTANTIALLY REDUCE CUSTOMER RADIOACTIVE WASTE MANAGEMENT LIFE-CYCLE COSTS. FOUNDED IN 2008, KURION IS BACKED BY LEADING ENERGY INVESTORS LUX CAPITAL MANAGEMENT AND FIRELAKE CAPITAL MANAGEMENT . HEADQUARTERED IN IRVINE, CA, KURION OPERATES A R&D FACILITY IN OAK RIDGE, TN AND A TEST FACILITY IN ROLLA, MO. FOR MORE INFORMATION, PLEASE VISIT WWW.KURION.COM .

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50247933&lang=en

Contact:

for Kurion, Inc.
Katie Wood Znameroski
Phone: +1-650-801-7952
Fax: +1-650-508-8336
Katie.Wood@Zenogroup.com
www.kurion.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release

Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi

IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release

IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei

CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s

NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release

NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates

Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release

As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye